Table 2 Variable selected in final CSHMs for aGVHD24, relapse and cGVHD, with their hazard ratios (HRs), confidence intervals (CI) and p values. All models were adjusted on the treatment variable (maraviroc).

aGVHD24

CD8\(^+\) EM CCR5\(^+\)

0.70

(0.56–0.89)

0.003

CD4\(^+\) Naive CCR5\(^+\)

1.37

(1.06–1.77)

0.02

Maraviroc

0.23

(0.067–0.78)

0.02

cGVHD

CD4\(^+\) EMRA CCR5\(^+\)

2.02

(0.93–4.39)

0.08

Recipient sex (ref=male)

0.09

(0.008–1.2)

0.07

Maraviroc

2.92

(0.24–36)

0.4

Relapse

B cell CD27\(^+\) \(\hbox {IgD}^-\)

2.87

(1.13–7.32)

0.03

NK CD16\(^\text {hi}\)

0.24

(0.067–0.83)

0.02

CD8\(^+\) EM CD27\(^-\)CD28\(^-\)

0.58

(0.37–0.89)

0.01

CD8\(^+\) EM CCR5\(^+\) in maraviroc recipients

1.73

(1.08–1.28)

0.02

Age donor

1.16

(1.05–1.28)

0.02

Maraviroc

1.20

(0.17–8.2)

0.9